Finland· FI-REL-REL730

Fulcin

A griseofulvin product containing griseofulvin, registered in Finland by AstraZeneca UK Limited. The same ATC class is registered in 3 of our 19 countries.

ATC D01BA01

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedFulcinATCD01BA01REGISTER NO.FI-REL-REL730PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Griseofulvin is registered in 3 of 19 countries.

Countries holding a registration under ATC D01BA01 (griseofulvin), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 2 of them publish a price we can compare per daily dose

Griseofulvin · ATC D01BA01

3 / 19 countries

  • Finlandprice
  • Ireland
  • Norwayprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Griseofulvin
Manufacturer
AstraZeneca UK Limited
Country
Finland (FI)
ATC code
D01BA01
ATC class
Griseofulvin
Defined daily dose
0.5 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

303 interactions on record for griseofulvin.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Griseofulvin · interactions on record

303 records

  • 21 severe
  • 262 moderate
  • 20 minor

Most severe, free to view

  • RanolazineC01EB18severe
  • IUP aus Plastik mit GestagenG02BA03severe
  • Levonorgestrel and ethinylestradiolG03AA07severe
  • Desogestrel and ethinylestradiolG03AA09severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Griseofulvin in 5 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All griseofulvin products

Authorised across Europe · EMA

The same active substance is authorised in 5 EEA countries. Names it is sold under:

  • Cyprus · Griseofulvin Remedica, Medofulvin
  • France · Grisefuline
  • United Kingdom (Northern Ireland) · Griseofulvin Brown & Burk Uk, Grisol
  • Ireland · Griseofulvin Brown & Burk Ir
  • Italy · Fulcin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/548a31e3-e254-432e-be44-0c6333584f83
GET /v1/drugs/548a31e3-e254-432e-be44-0c6333584f83?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.5",
  "form": "tabletti",
  "route": null,
  "ddd_unit": "g",
  "strength": "500 mg",
  "atc_label": "griseofulviini",
  "ma_number": "5854",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL730",
  "authorised_at": "1969-09-10"
}

See everything about griseofulvin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.